Evidence map›Paper›PMID 37182121›Full record

ArticleEuropean urology open science2023

US Food and Drug Administration Warning Regarding Finasteride and Suicidal Ideation: What Should Urologists Know?

Haidar Al Saffar, Jennifer Xu, Jonathan S O'Brien, Brian D Kelly, Declan G Murphy, Nathan Lawrentschuk

Open access · goldAbstract read
In one paragraph

Article in European urology open science, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.7field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Post-finasteride syndrome - a true clinical entity?International journal of impotence research · 2025
    Review
  6. Review
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Haidar Al SaffarDepartment of Genitourinary Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Australia.
Jennifer XuDepartment of Genitourinary Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Australia.
Jonathan S O'BrienDepartment of Genitourinary Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Australia.
Brian D KellyDepartment of Genitourinary Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Australia.
Declan G MurphyDepartment of Genitourinary Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Australia.
Nathan LawrentschukDepartment of Genitourinary Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Australia.
Peter MacCallum Cancer Centre · AUEastern Health · AUEpworth Hospital · AUSt Vincent's Hospital · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Finasteride competitively inhibits 5α-reductase (5-AR) isoenzymes, which blocks dihydrotestosterone (DHT) production, thereby reducing DHT. Finasteride is used in the management of benign prostatic hyperplasia (BPH) and androgenic alopecia. Amid patient reports of suicidal ideation (SI), the Post Finasteride Syndrome advocacy group has petitioned for either a stop to selling of the drug or advertisement of stronger warnings. The US Food and Drug Administration recently added SI to the adverse effects listed for finasteride. Here we provide a brief but comprehensive review of the literature on the psychological side effects of 5-AR inhibitors (5-ARIs) to provide an opinion to help in guiding treating urologists. Most of the current evidence, obtained from the literature on dermatology, suggests that 5-ARI users experience a higher rate of depressive symptoms. However, given the lack of comprehensive randomised studies, the causal link between finasteride and SI remains unclear. Urologists prescribing 5-ARIs should be aware of the recent addition of suicide and SI risk to the list of side effects. A mental health screen should be performed and appropriate resources provided to patients commencing treatment. Furthermore, a review should be arranged with the general practitioner to assess new-onset mental health or SI symptoms. Patient summary: We provide recommendations for urologists who prescribe finasteride for the treatment of benign prostate enlargement. Urologists should be aware of the recent addition of suicidal ideation to the list of side effects for this drug. Finasteride prescription should be continued; however, we recommend a detailed medical history to screen for prior mental health and personality disorders, with discontinuation of the medication in patients with new onset of depression or suicidal symptoms. Close liaison with the patient's general practitioner is vital for management of depressive or suicidal symptoms.

Indexed as

Adverse effectAdverse event reporting systemAndrogenic alopeciaBenign prostatic hyperplasiaDihydrotestosteroneFinasterideFood and Drug AdministrationLower urinary tract symptoms

Identifiers

PMID37182121
PMCPMC10172713
OpenAlexW4367399848

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.